These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7846014)

  • 1. CA19-9: the Italian experience.
    Gullo L
    Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
    Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA19-9 determination in the management of pancreatic cancer.
    van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J
    Hepatogastroenterology; 1996; 43(9):710-3. PubMed ID: 8799418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma].
    Zhang Y; Ji SR; Feng DX; Ji J; Han TQ
    Ai Zheng; 2003 Mar; 22(3):295-7. PubMed ID: 12654190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CA19-9 has no value as a tumor marker in obstructive jaundice].
    Peterli R; Meyer-Wyss B; Herzog U; Tondelli P
    Schweiz Med Wochenschr; 1999 Jan; 129(3):77-9. PubMed ID: 10065510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
    Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
    Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
    Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying markers for pancreatic cancer by gene expression analysis.
    Zhou W; Sokoll LJ; Bruzek DJ; Zhang L; Velculescu VE; Goldin SB; Hruban RH; Kern SE; Hamilton SR; Chan DW; Vogelstein B; Kinzler KW
    Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):109-12. PubMed ID: 9488584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer.
    Wu D; Qian JM; Deng RX; Jiang WJ; Chen YJ; Liu XH; Lu XH
    Chin J Dig Dis; 2006; 7(2):117-20. PubMed ID: 16643340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
    Gold DV; Modrak DE; Ying Z; Cardillo TM; Sharkey RM; Goldenberg DM
    J Clin Oncol; 2006 Jan; 24(2):252-8. PubMed ID: 16344318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
    Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
    Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary.
    Pezzilli R; Casadei R; Calculli L; Santini D; Morselli-Labate AM;
    Dig Liver Dis; 2010 Jan; 42(1):73-4. PubMed ID: 19473891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.